CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 328 enrolled
Drug / intervention
Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01357616
NCT01357616Phase 3Completed
CompareCT.gov

Comparison of Efficacy and Safety of Brinzolamide/Timolol Fixed Combination (AZARGA™) vs Brinzolamide (AZOPT®) and Timolol in Chinese Subjects With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research·interventional·Posted May 20, 2011·Updated Apr 10, 2014

In Brief

A Phase 3 clinical trial evaluating Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 328 participants.

Detailed Summary

The purpose of this study was to compare the intraocular pressure (IOP)-lowering efficacy and safety of AZARGA™ (Brinzolamide 1%/Timolol 0.5% Ophthalmic Suspension), dosed twice daily versus AZOPT® (Brinzolamide 1% Ophthalmic Suspension) and Timolol 0.5% Ophthalmic Solution, each dosed twice daily, in Chinese patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2011
Enrollment StartNov 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 15.1 years ago

Interventions

Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspensiondrug

Brinzolamide 1% ophthalmic suspensiondrug

Timolol 0.5% ophthalmic solutiondrug